The prostate prognostic test was part of the Prost
Post# of 148323
(Total Views: 164)
Posted On: 03/29/2019 6:29:57 PM
Re: ClosetInvestor #1475
The prostate prognostic test was part of the ProstaGene acquisition. Yes $750M is an accurate estimate based on RP stating that 250,000 men have this test annually (total) and estimating $3,000 per test. This test is more accurate and could likely be priced higher, but 100% penetration is what the $750M figure is based on.
Like leronlimab, we don't have a sales force, so a license agreement seems likely. It requires FDA approval still, but based on my previous research these 510-k approval average around 5 months.
Like leronlimab, we don't have a sales force, so a license agreement seems likely. It requires FDA approval still, but based on my previous research these 510-k approval average around 5 months.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Scroll down for more posts ▼